Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina

Yakugaku Zasshi. 2021;141(12):1307-1317. doi: 10.1248/yakushi.21-00158-1.ABSTRACTThe number of patients with exudative age-related macular degeneration, diabetic retinopathy and retinal vein occlusion is expected to rise in proportion with the aging of the population and increasing diabetes patients. Also, they are the most common diseases caused by intraocular neovascularization and are often difficult to treat. Currently, anti-vascular endothelial growth factor (VEGF) therapy has been developed and has demonstrated excellent results in treating macular edema, and many patients have avoided blindness. Unfortunately, there are problems with cases that do not respond to the anti-VEGF drugs and complications of administration. It is necessary to deepen the understanding of the physiological and pathological retinal roles of VEGF and to optimize the anti-VEGF therapy. There are also no drugs indicated for the regression of neovascularization itself. The solution to this problem is to develop novel therapies targeting other than VEGF. In this symposium review, we introduce the roles of VEGF in the ischemic retina and anti-angiogenic factors as promising therapeutic targets.PMID:34853203 | DOI:10.1248/yakushi.21-00158-1
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Journal of Innovative Optical Health Sciences, Ahead of Print. Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) are two common retinal diseases for elder people that may ultimately cause irreversible blindness. Timely and accurate diagnosis is essential for the treatment of these diseases. In recent years, computer-aided diagnosis (CAD) has been deeply  investigated and effectively used for rapid and early diagnosis. In this paper, we proposed a method of CAD using vision transformer to analyze optical coherence tomography (OCT) images and to automatically discriminate AMD, DME, a...
Source: Journal of Innovative Optical Health Sciences - Category: Biomedical Science Authors: Source Type: research
This study aims to estimate the availability of anti-VEGF treatment for patients with AMD and DME and demand for intravitreal injections (IVI) in the Russian Federation.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Conclusion: In this study, for the first time, we proposed a method for developing a sustained-release intraocular implant, consisting of ranibizumab by the heating method. This method allows for the industrial production of ranibizumab by extrusion and eliminates the complications related to reservoir systems.PMID:34888210 | PMC:PMC8642803 | DOI:10.34172/apb.2021.072
Source: Adv Data - Category: Epidemiology Authors: Source Type: research
Acquired retinal diseases such as age-related macular degeneration and diabetic retinopathy rank among the leading causes of blindness and visual loss worldwide. Effective treatments for these conditions are available, but often have a high treatment burden, and poor compliance can lead to disappointing real-world outcomes. Development of new treatment strategies that provide more durable treatment effects could help to address some of these unmet needs. Gene-based therapeutics, pioneered for the treatment of monogenic inherited retinal disease, are being actively investigated as new treatments for acquired retinal disease...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Yakugaku Zasshi. 2021;141(12):1307-1317. doi: 10.1248/yakushi.21-00158-1.ABSTRACTThe number of patients with exudative age-related macular degeneration, diabetic retinopathy and retinal vein occlusion is expected to rise in proportion with the aging of the population and increasing diabetes patients. Also, they are the most common diseases caused by intraocular neovascularization and are often difficult to treat. Currently, anti-vascular endothelial growth factor (VEGF) therapy has been developed and has demonstrated excellent results in treating macular edema, and many patients have avoided blindness. Unfortunately, there...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Blindness | Diabetes | Drugs & Pharmacology | Endocrinology | Japan Health | Opthalmology | Vitamin A